http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_85e05febe80244264dfb026f17b3cffd
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Fine |
| name | Howard A. Fine Howard A Fine |
| given-name | Howard A Howard A. |
| organization-name | Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College New York NY From the New Approaches to Brain Tumor Therapy CNS Consortium, Baltimore, MD. Neuro-Oncology Branch, National Cancer Institute, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.; New York University Cancer Institute, New York University Langone Medical Center, New York, USA. Neuro-Oncology Branch, National Cancer Institute, National Institutes of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD Neuro-Oncology Branch, National Cancer Institute, National Institutes of Neurological Disorder and Stroke, National Institutes of Health, Bethesda, MD 2Center for Cancer Research, Neuro-Oncology Branch, National Cancer Institute, Bethesda, Maryland; and Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892. 2Neuro-oncology Branch, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, Maryland; Department of Neurology, New York–Presbyterian Hospital, Weill Cornell Medicine, New York, NY. Laura & Isaac Perlmutter Cancer Center NYU Langone Medical Center New York New York 1Neuro-Oncology Branch and Gregory Masters, Helen F. Graham Cancer Center, Newark, DE; Lada Krilov and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Howard H. Bailey, University of Wisconsin Hospital and Clinics, Madison, WI; Marcia S. Brose, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Harold Burstein and Lisa R. Diller, Dana-Farber Cancer Institute; Don S. Dizon, Massachusetts General Hospital, Boston, MA; Howard A. Fine, New York University Langone Medical Center; Gary K.... From the Center for Neuro-OncologyDana-Farber Cancer Institute, and Departments of Neurology, Surgery, and Radiation Oncology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; Department of Neuro-Oncology, M.D. Anderson Cancer Center, and National Central Nervous System Consortium, Houston, TX; and Cancer Treatment and Evaluation Program, Investigational Drug Branch, Division of Cancer Therapy and Diagnosis, National Cancer Institute, Bethesda MD. From the Neuro-Oncology Branch, Radiation Oncology Branch and Biometric Branch, National Cancer Institute; Surgical Neurology Branch, National Institutes of Neurological Disorders and Stroke; and the Department of Radiology, the Clinical Center, National Institutes of Health, Bethesda, MD. From the University of Heidelberg, Germany; The University of Texas M.D. Anderson Cancer Center, Houston, TX; H. Lee Moffitt Cancer Center, Tampa, FL; Erasmus Medisch Centrum, Rotterdam, the Netherlands; Hopital Pitie Salpetriere, Paris, France; Austin Health, Victoria, Australia; Princess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada; Eli Lilly and Company, Indianapolis, IN; and Neuro-Oncology Branch, National Cancer Institute, Bethesda, MD. Department of Neurology New York Presbyterian Hospital—Cornell New York NY Meyer Cancer Center, Division of Neuro-Oncology, Department of Neurology, New York-Presbyterian Hospital/Weill Cornell Medicine, New York, New York, USA Department of Neurology NewYork Presbyterian–Weill Cornell Medicine New York New York USA Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College, New York, NY 1Neuro-Oncology Branch, National Cancer Institute and From the Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; the Neuro-Oncology Branch, National Cancer Institute and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; and the Experimental Neuroimaging Section, Laboratory of Diagnostic Radiology Research, National Institutes of Health, Bethesda, MD. 3Neuro-oncology Branch, and 1Neuro-Oncology Branch and; 3Surgical Neurology Branch, National Institutes of Neurological Disorder and Stroke, NIH, Bethesda, Maryland Neuro-oncology Branch, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA Neuro-Oncology Branch, National Cancer Institute, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.; New York University Cancer Institute, New York University Langone Medical Center, New York, New York, USA. Department of Neurology and the Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY 10065; Neuro-Oncology Branch, National Cancer Institute, National Institutes of Neurological Disorder and Stroke, NIH, Bethesda, Maryland Authors' Affiliations: Neuro-Oncology Branch, National Cancer Institute, National Institutes of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland From the Surgical and Molecular Neuro-oncology Unit, National Institute of Neurological Disorders and Stroke, Neuro-oncology Branch, National Cancer Institute, and National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD; and the Brigham and Women's Hospital, Boston, MA. Neuro-Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland Neuro-Oncology Branch, National Cancer Institute, National Institute of Neurologic Disorder and Stroke, National Institutes of Health, Bethesda, MD 20892 1Neuro-Oncology Branch, National Cancer Institute; Division of Hematology and Oncology, The New York University (NYU) Langone Medical Center, New York, New York. Meyer Cancer Center, Division of Neuro-Oncology, Department of Neurology, NewYork-Presbyterian Hospital/Weill Cornell Medicine, New York, New York; and 1Neuro-Oncology Branch, National Cancer Institute and; 2National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland; and 1Neuro-Oncology Branch, National Cancer Institute, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, and 1 Neuro-Oncology Branch, National Cancer Institute, National Institute of Neurological Disease and Stroke, National Institutes of Health, Bethesda, MD and 2Carnegie-Mellon University, Pittsburgh, PA, USA 1Neuro-Oncology Branch, National Cancer Institute, National Institutes of Neurological Disorder and Stroke, NIH, Bethesda, Maryland and Department of Neurology, Weill Cornell Medicine NewYork–Presbyterian Hospital New York NY 3Department of Neurology, Weill Cornell Medicine, New York, New York. 1 Neuro-Oncology Branch, National Cancer Institute, National Institute of Neurological Diseases and Stroke Brain and Spine Center, Weill Cornell Medicine, New York, New York, USA Authors' Affiliations: 1Division of Cancer Epidemiology and Genetics and 2Neuro-oncology Branch, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, Maryland; 3Division of Cancer Etiology, Department of Population Sciences, City of Hope National Medical Center and The Beckman Research Institute, Duarte, California; and 4Core Genotyping Facility, Advanced Technology Program, SAIC Frederick, Inc., National Cancer Institute-Frederick, Frederick, Maryland Authors' Affiliations: 1Human Oncology and Pathogenesis Program, 2Department of Neurology, 3Analytical Pharmacology Core, and 4Department of Neurosurgery, Memorial Sloan-Kettering Cancer Center and 5Department of Pharmacology, Weill-Cornell Medical College, New York, New York; Departments of 6Neurology, 7Neurosurgery, 8Pathology and Laboratory Medicine, 9Human Genetics and Biostatistics, and 10Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California; 11University of Wisconsin-Madison, Madison, Wisconsin; 12University of Pittsburgh, Pittsburgh, Pennsylvania; 13University of Texas MD Anderson Cancer Center, Houston, and 14University of Texas Health Science Center at San Antonio, San Antonio, Texas; 15Dana-Farber Cancer Institute, Boston, Massachusetts; 16University of California, San Francisco; 17NeuroOncology Branch; National Cancer Institute, Bethesda, Maryland; and 18Northwestern University, Chicago, Illinois Weill Cornell Medicine, New York, New York. Division of Neuro-Oncology, Director of the Brain Tumor Center, New York-Presbyterian Hospital/Weill Cornell Medical Center, 1305 York Avenue, 9th Floor, New York, NY 10021, USA From the Neuro-Oncology Branch, National Cancer Institute, National Institutes of Neurologic Disorder and Stroke, and Cancer Therapeutics Branch and the Cancer Prevention Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD; and Center for Neuro-Oncology, Dana-Farber Cancer Institute, Department of Neurology the Brigham and Women’s Hospital, and the Massachusetts General Hospital, Harvard Medical School, Boston, MA. 3Neuro-Oncology Branch, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, Maryland; 10Neuro-Oncology Branch, NIH, Bethesda, Maryland; Department of Neurology, The Meyer Cancer Center, Weill Cornell Medicine, New York, New York. From the Neuro-Oncology Branch, National Cancer Institute, and Laboratory of Neurophysiology, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; and the Departments of Pediatrics and Medicine, University of Medicine and Dentistry of New Jersey (UMDNJ)/Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, New Brunswick, NJ. |
Incoming Links
Showing number of triples: 1 to 223 of 223.